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Background: The current investigation sought to explore the nature of the secondary metabolites in the algae,
Laurencia pacifica.
Results: This report details the first isolation of the sesquiterpenes isoaplysin (1), isolaurenisol (2), debromoisolaurinterol
(3), debromoaplysinol (4), laur-11-en-10-ol (5), 10α-hydroxyldebromoepiaplysin (6), and the previously unknown
10-bromo-3,7,11,11-tetramethylspiro[5.5]undeca-1,7-dien-3-ol (7) from the algae, Laurencia pacifica. Isoaplysin (1)
and debromoaplysinol (4) showed promising levels of growth inhibition against a panel cancer-derived cell lines of
colon (HT29), glioblastoma (U87, SJ-G2), breast (MCF-7), ovarian (A2780), lung (H460), skin (A431), prostate (Du145),
neuroblastoma (BE2-C), pancreas (MIA), murine glioblastoma (SMA) origin with average GI50 values of 23 and 14 μM.
Conclusions: Isoaplysin (1) and debromoaplysinol (4) were up to fourfold more potent in cancer-derived cell
populations than in non-tumor-derived normal cells (MCF10A). These analogues are promising candidates for
anticancer drug development.
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Introduction
Natural products with their high fraction sp3 content (Fsp3)
represent a significant proportion of all clinical drugs [1].
Of the 1,355 new entities introduced as therapeutics
between 1981 and 2010, 71% were natural products or
natural product derived [2]. A high Fsp3 content imbues
natural products with defined three-dimensional geometry
that allows for high levels of interaction with a wide range
of biological targets. A significant number of natural prod-
ucts adhere to the ‘rule of five’ and thus present high levels
of drug-like character [3,4]. Natural products also afford
access to a wide range of novel chemical motifs accessing
new chemical space in the drug design and development
arena. This has led to the ongoing interest in accessing
natural product secondary metabolites (in particular) with
their high chemical diversity and biological specificity,
making them a favorable source of lead compounds for
drug discovery and development [5,6].
Recently, we turned our attention to marine natural
products as a potential source for new lead compounds.* Correspondence: Adam.McCluskey@newcastle.edu.au
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reproduction in any medium, provided the origIn this area, we have identified a small family of cytotoxic
steroids from an Australian sponge Psammoclema sp. [7],
and antimalarial, antialgal, antitubercular, antibacterial,
antiphotosynthetic, and antifouling activity of diterpene
and diterpene isonitriles from the tropical marine sponge
Cymbastela hooperi [8]. In this present study, we exam-
ined the cytotoxicity of extracts obtained from Laurencia
pacifica algae collected in the pacific coast of the Baja
California Peninsula, Mexico.
The genus Laurencia typically inhabits the world's
tropical oceans and has been responsible for approximately
half of all the reported compounds from red algae. This
genus is considered an important producer of haloge-
nated sesquiterpenes, diterpenes, and acetogenins [9-11].
Biological activities of the Laurencia family range from
antipredatory [12], antifungal [13], antibacterial [14-16],
to anticancer [17-19]. Secondary metabolites reported
from L. pacifica include γ-bisabolene, bromocuparane,
laurinterol, debromolauriterol, isolaurinterol, aplysin, debro-
moaplysin, 10-bromo-α-chamigrene, prepacifenol, pacifenol,
pacifidine, and kylinone [10].
Results and discussion
The algae, L. pacifica was collected from the Baja California
Peninsula, Mexico. The ethanol extracts were examined foris is an Open Access article distributed under the terms of the Creative
mmons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
inal work is properly credited.
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icity screening was conducted against a panel of cancer
cell lines of colon (HT29), glioblastoma (U87, SJ-G2),
breast (MCF-7), ovarian (A2780), lung (H460), skin (A431),
prostate (Du145), neuroblastoma (BE2-C), pancreas (MIA),
murine glioblastoma (SMA) origin, and a normal line of
breast cells (MCF10A) [20]. The preliminary screening
showed sufficient promise to embark on an isolation
program (data not shown).
Bioassay-guided fractionation (normal phase chromatog-
raphy) of the L. pacifica ethanolic extracts (see Additional
file 1) resulted in the isolation of seven sesquiterpenes:
isoaplysin (1) [21,22], isolaurenisol (2) [13,22], debro-
moisolaurinterol (3) [23], debromoaplysinol (4) [10,13,21],
laur-11-en-10-ol (5) [13], 10α-hydroxyldebromoepiaplysin
(6) [13] (Figure 1) and the previously unreported 10-
bromo-1,7-dien-3-ol (7) (Figure 2). Sesquiterpenes 1 to 6
were identified in comparison with their spectroscopic
data against literature data [21-23].
Sesquiterpenes 1 to 6 have been found in other Lauren-
cia algae: L. okumurai, (1, 2, 3, 4, and 6) [21,22], L. gracilis
(2) [24,25], L. tristicha (5) [19], and L. distichophylla (3)
[26]. This work represents the first identification of these
sequiterpenes in L. pacifica.
Sesquiterpene 7 was isolated in very small quantities
(approximately 100 ng) from 2 kg of algae and was iden-
tified through a combination of high resolution mass
spectrometry, infrared spectroscopy, and heteronuclear
multiple bond correlation (HMBC), heteronuclear single
quantum correlation (HSQC), correlated spectroscopy
(COSY) NMR (see Additional file 1). The spectral data
obtained closely matched reported spectral data of
the related 10-bromo-7,8-expoxychamigr-1-en-3-ol (8)
(Figure 2) [26], in which the C6 stereochemistry was
determined by detailed NMR analysis and was consistent
with our data [27-29]. The peak assignment and spectral
comparison of 7 and 8 are shown in Table 1. There are








Figure 1 Chemical structures of the known sesquiterpenes isolated fr
debromoisolaurinterol (3), debromoaplysinol (4), laur-11-en-10-ol (5), and 1of which is supported by crystal structure data and is of
the same absolute configuration as shown for 7 and 8.
While these data are wholly consistent with our assign-
ment, Suescun et al. have identified another compound
with the opposite C6 configuration [29]. We thus consider
our absolute configuration assignment as tentative. Not-
withstanding this, the spectroscopic data is consistent with
the assigned structure and represents a new sesquiterpene
from L. pacifica (Figure 2).
Sequiterpenes 1 to 5 were isolated in sufficient quantities
allowing direct evaluation as pure compounds against a
panel of cancer and non-cancer-derived cell lines. Due
to the low levels of sesquiterpenes 6 and 7, these were
screened as a 1:1 mixture (both were isolated from the
same extract fraction as determined by 1H NMR) [30].
Initial cytotoxicity screening was conducted at a single
dose of 25 μM, and these data are presented in Table 2.
Analysis of the cytotoxicity data presented in Table 2
highlights the low level of cell death of the 12 cell lines
examined on treatment with 2, 3, 5, and 6/7. Isoaplysin
(1) and debromoaplysinol (4) displayed promising levels
of cell death from 10% to >100% and 31% to >100% at
25 μM drug concentration, respectively. Of the other
analogues, only isolaurenisol (2) displayed any growth
inhibition at >20% (Du145, prostate cancer cell line).
Given the activities of these three analogues, a full dose
response evaluation was undertaken across our panel of
carcinoma and normal cell lines [20]. These data are
presented in Table 3.
As anticipated, isolaurenisol (2) displayed no noteworthy
cytotoxicity returning a GI50 value > 50 μM across all cell
lines examined. Both isoaplysin (1) and debromoaplysinol
(4) displayed good to excellent levels of cytotoxicity.
Isoaplysin (1) returned an average GI50 value of 23 μM
(from 15 ± 1.2 μM to 40 ± 0.6 μM against the HT29 and
U87 cell lines, respectively), while debromoaplysinol (4)
returned an average GI50 value of 14 μM (from 6.8 ±






























Figure 2 Important HMBC (blue arrows) and COSY (bold bonds) correlations for 7, and the chemical structure of the related
10-bromo-7,8-epoxychamigr-1-en-3-ol (8).
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lines. Both compounds showed the greatest growth inhibi-
tory effect in the prostate cancer-derived cell line Du145
with GI50 values of 12 and 6.8 μM, respectively, and the
least growth inhibitory effect in the non-cancer-derived
normal breast cells with GI50 values of 46 and 28 μM,
respectively. Indeed, 1 and 4 were up to fourfold more
potent in cancer-derived cell populations than normal
cells, imbuing them with properties favorable for future





a typeb δH (H, multi, J Hz)
1H-1H COSY
1 136.4, CH 5.84 (1H, d, 10.4) 2
2 131.1, CH 5.53 (1H, d, 10.4) 1
3 67.5, qC - -
4 36.1, CH2 1.80 (1H, m), 1.73 (1H, m) 5
5 28.2, CH2 1.98 (2H, m) 4
6 48.0, qC - -
7 139.0, qC - -
8 120.2, CH 5.22 (1H, s) 9, 14
9 35.8, CH2 2.78 (1H, m), 2.56 (1H, m) 8, 10
10 62.0, CH 4.63 (1H, dd, 10.8, 6.3) 9b
11 41.5, qC - -
12 17.8, CH3 1.01 (3H, s) 13
13 26.1, CH3 1.10 (3H, s) 12
14 21.7, CH3 1.55 (3H, s) 9
15 28.6, CH3 1.29 (3H, bs) -
aData recorded in CDCl3 calibrated at δH 7.24 ppm an for δc 77.0 for residual solve
proton while ‘b’ denotes the up field proton; cchemical shift for the carbons was inGiven the structural similarity of the isolated analogues
(1 to 6), being direct structural homologues or biosyn-
thetically related, the observed differences in cytotoxicity
suggest that the presence of the furan moiety and position-
ing and nature of the pendent substituents was important
for cytotoxicity. Analogues 1 and 4 are Br −OH bioisos-
teres, and 4 and 6 are positional isomers (C3a-OH (1) and
a C10a-OH (6)). The position of the −OH moiety is clearly
important with the 3α-hydroxydebromoaplysin (6) devoid





c δH (multi, J Hz)
6 136.1 5.84 (dd, 10.4, 1.0)
3, 6, 15 131.3 5.73 (dd, 10.4, 1.6)
- 66.8 -
3 35.0 1.79 (m), 1.81 (m)
3, 6 23.1 1.69 (ddd, 13.2, 11.2, 4.7), 1.94 (d, 13.2)
- 45.9 -
- 60.5 -
- 61.4 2.97 (d, 3.0)
- 35.1 2.40 (ddd, 15.4, 11.4, 3.0), 2.69 (dd, 15.4, 5.8)
12 58.4 4.28 (dd, 11.4, 5.8)
- 40.0 -
13 18.2 1.08 (s)
6, 10, 12 25.8 0.98 (s)
26.0 1.17 (s)
29.3 1.33 (s)
nt; bin the case of a diasterotopic pair of hydrogens, ‘a’ denotes the downfield
ferred from HSQC and HMBC data.
Table 2 Percentage growth inhibition by sesquiterpenes
(1 to 7)
Compound
Cell line 1 2 3 4 5 6/7
HT29a 60 ± 3 12 ± 2 12 ± 5 >100 <10 10 ± 5
U87b 25 ± 2 13 ± 6 15 ± 7 52 ± 2 12 ± 4 15 ± 6
MCF-7c 81 ± 6 <10 <10 >100 <10 <10
A2780d 65 ± 5 <10 <10 99 ± 1 <10 <10
H460e 11 ± 1 <10 <10 71 ± 1 <10 <10
A431f 86 ± 1 <10 <10 >100 <10 <10
Du145g 41 ± 1 23 ± 6 18 ± 3 92 ± 2 18 ± 2 17 ± 3
BE2-Ch >100 <10 <10 >100 <10 <10
SJ-G2b 40 ± 5 <10 10 ± 3 >100 12 ± 3 14 ± 3
MIAi 47 ± 2 12 ± 4 17 ± 3 92 ± 2 18 ± 3 19 ± 2
SMAj 34 ± 8 <10 <10 95 ± 1 <10 <10
MCF10Ak 10 ± 6 <10 <10 31 ± 10 <10 <10
Isoaplysin (1), isolaurenisol (2), debromoisolaurinterol (3), debromoaplysinol
(4), laur-11-en-10-ol (5), and a 1:1 mixture of the 3α-hydroxydebromoaplysin
(6) and 10-bromo-1,7-dien-3-ol (7) against a panel of cancer and non-cancer
derived cell lines at a single dose (25 μM). Values are measured relative to an
untreated control. aColon; bglioblastoma; cbreast; dovarian; elung; fskin; gprostate;
hneuroblastoma; ipancreas; jglioblastoma (murine); kbreast (normal).
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against the HT29 (9.1 μM), A431 (9.6 μM), and Du145
(6.8 μM) cell lines [31]. Isoaplysin (1) and debromoaplysi-
nol (4) differ only in the presence of the C3a-Br (1) and a
C3a-OH (4) moiety, and 4 displays enhanced specific and
broad spectrum cytotoxicity relative to 1, suggesting thatTable 3 Growth inhibition (GI50 μM) of isoaplysin (1),
isolaurenisol (2), and debromoaplysinol (4) against a
panel of cancer and non-cancer derived cell lines
Compound
Cell line 1 2 4
HT29a 15 ± 1.2 >50 9.1 ± 1.1
U87b 40 ± 0.6 >50 26 ± 1.7
MCF-7c 20 ± 1.3 >50 14 ± 1.7
A2780d 17 ± 0.6 >50 10 ± 1.7
H460e 34 ± 1.2 >50 18 ± 0.3
A431f 17 ± 0.6 >50 9.6 ± 0.9
Du145g 12 ± 0.3 >50 6.8 ± 0.3
BE2-Ch 27 ± 2.3 >50 13 ± 0.9
SJ-G2b 29 ± 0.7 >50 15 ± 0.7
MIAi 23 ± 1.5 >50 16 ± 0.7
SMAj 24 ± 3.8 >50 14 ± 1.2
MCF10Ak 46 ± 3.2 >50 28 ± 1.0
GI50 is the concentration of drug that reduces cell growth by 50%.
aColon;
bglioblastoma; cbreast; dovarian; elung; fskin; gprostate; hneuroblastoma;
ipancreas; jglioblastoma (murine); kbreast (normal).the −OH moiety enhances the cytotoxicity of this class
of compounds.
Sun et al. isolated and screened the related sesquiter-
penes: aplysin-9-ene, epiaplysinol, debromoepiaplysinol,
aplysinol, and aplysin isolated from Laurencia tristicha
in a MTT assay against lung adenocarcinoma (A549),
stomach cancer (BGC-823), hepatoma (Bel 7402), colon
cancer (HCT-8), and HeLa cell lines [19]. Interestingly,
only debromoepiaplysinol (epi-4, this work) displayed
cytotoxicity with a GI50 = 15.5 μM against HeLa cells,
where as herein, debromoaplysinol (4) displays activity
across our panel of 11 cancer cell lines with strong activity
in the HT29 (9.1 μM), A431 (9.6 μM), and Du145
(6.8 μM) cells [19]. These findings serve to emphasize
the subtle nature of drug-ligand interactions and the
role of stereochemistry in eliciting biological activity, c.f.
1, 4, and 6.
Conclusions
Herein, we have identified sesquiterpenes 1 to 6 for the
first time in L. pacifica and isolated a new sesquiterpene
and 10-bromo-1,7-dien-3-ol (7). Screening of these ana-
logues against 11 cancer cell lines revealed modest to good
levels of cytotoxicity for 1 and 4, with up to fourfold select-
ivity towards cancer-derived cell populations compared
with normal cells. Given the low molecular weights and
high Fsp3 content, the structure activity data elucidated
in this small subset of analogues, we believe that 1 and 4
represent excellent leads for the development of selective
and potent anticancer agents [31].
Experimental
General experimental Solvents. Solvents used for TLC,
speedy column, and centrifugal chromatography were of
bulk quality and were distilled from glass prior to use. In
the case of HPLC, all of the solvents were HPLC grade
and were filtered and degassed prior to their use. The
solvent referred as LP (light petroleum), is a mixture of
different alkanes with a boiling point 60°C to 80°C.
Collection of the Mexican algae L. pacifica algae were
collected on the coast of the Baja California Peninsula,
Mexico. The algae was cleaned of epiphytes, rinsed with
fresh water, and dried in the sun at the collection site.
The specimens were stored at −20°C. A voucher specimen
of L. pacifica was preserved on location in 5% formalde-
hyde and deposited in a private collection at the Algal
Laboratory in the Interdisciplinary Center of Marine
Sciences (CICIMAR), La Paz, B.C.S., Mexico, for taxo-
nomical identification and future reference. Subsequently,
in the laboratory, 10 g of dry algae was roughly torn or cut
to small pieces and then ground with a mortar and pestle.
The powdered algae was then submerged in 250 mL of
ethanol. The mixture was left for 48 h at 25°C to 35°C.
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tissue was extracted again under the same conditions.
Both filtered extracts were combined and concentrated
to dryness under reduced pressure at 40°C to obtain ca
30 mg of extract. These extracts were used for biological
screening.
Extracts of L. pacifica and its fractionation Crude extract
of L. pacifica 2 kg of algae was reduced to small pieces
of ca as before, and then submerged in 1 L of ethanol.
The resulting mixture was left for 48 h at 25°C to 35°C.
Afterwards, the mixture was filtered and the residual
algal tissue was extracted again under the same condi-
tions. Both filtered extracts were combined and concen-
trated to dryness under reduced pressure at 40°C to
obtain 2.2 g of extract. Fractionation of the crude
extract was commenced with a speedy column resulting
in 18 fractions [32]. All fractions were tested in the colori-
metric assay; active fractions were then fractionated in
normal phase HPLC until isolation of a pure compound.
NMR Proton and 13C NMR spectra were recorded on a
Bruker Ascend 400 or Bruker Ascend 600 (Madison,
WI, USA). All NMR spectra were recorded as CDCl3
solutions; the solvent signal was used as internal stand-
ard for chemical shifts (13C δ 77.0 ppm, and 1H δ
7.24 ppm for the residual CHCl3 proton). All spectra,
including HSQC, HMBC, distortionless enhancement
by polarization transfer (DEPT135), distortionless enhance-
ment by polarization transfer with retention of quaternaries
(DEPTQ135), and (homonuclear) COSY-utilized standard
Bruker pulse programs.
Cell culture and stock solutions Stock solutions were
prepared as follows and stored at −20°C: drugs were
stored as 20 mM solutions in DMSO. All cell lines were
cultured at 37°C, under 5% CO2 in air. All cancer-derived
cells lines were maintained in Dulbecco's modified Eagle's
medium (Trace Biosciences, Sydney, Australia) supple-
mented with 10% fetal bovine serum, 10 mM sodium
bicarbonate, penicillin (100 IU/mL), streptomycin (100 μg/
mL), and glutamine (4 mM). The non-cancer-derived
breast cell line MCF10A was maintained in Dulbecco's
modified Eagle's medium and Ham's F12 medium (1:1,
Trace Biosciences, Sydney, Australia) supplemented with
5% heat inactivated horse serum, HEPES (20 mM), peni-
cillin (100 IU/ml), streptomycin (100 μg/mL), glutamine
(2 mM), epidermal growth factor (20 ng/ml), hydrocorti-
sone (500 mg/ml), cholera toxin (100 ng/ml), and insulin
(10 μg/mL).
In vitro growth inhibition assay Cells in logarithmic
growth were transferred to 96-well plates. Cytotoxicity
was determined by plating cells in duplicate in 100 mLmedium at a density of 2,500 to 4,000 cells/well. On day
0, (24 h after plating) when the cells were in logarithmic
growth, 100 μL medium with or without the test agent
was added to each well. After 72 h, drug exposure growth
inhibitory effects were evaluated using the MTT (3-[4,5-
dimethyltiazol-2-yl]-2,5-diphenyl-tetrazolium bromide) assay
and absorbance read at 540 nm. Percentage growth inhib-
ition was determined at a fixed drug concentration of
25 μM. A value of 100% is indicative of total cell growth
inhibition. Those analogues showing appreciable percent-
age growth inhibition underwent further dose response
analysis allowing for the calculation of a GI50 value. This
value is the drug concentration at which cell growth is
50% inhibited based on the difference between the optical




Isolated as a white powder: 1.5 mg; [α] 20D = −5.3° (c
0.001, CH3OH); IRνmax 2,927 (C–H), 2,858, 1,620 (C = C),
1,593 (C = C), 1,499, 1,453 (C = C), 1,423, 1,376 (C–H),
1,268 (C–O), 1,135, 946 cm−1; 1H NMR (400 MHz,
CDCl3) δ 6.88 (d, J = 7.6 Hz, 1H, H-5), 6.66 (dd, J = 7.5,
0.7 Hz, 1H, H-4), 6.58 (s, 1H, H-2), 3.66, 3.56 (ABq,
JAB = 11.1 Hz, 2H, H-12), 2.27 (s, 3H, H-15), 2.21 to
2.12 (m, 1H, H-10), 1.90 to 1.83 (m, 1H, H-8a), 1.70 to
1.60 (m, 2H, H-8b, H-9a), 1.50 (s, 3H, H-14), 1.20 to 1.13
(m, 1H, H-9b), 1.10 (d, J = 6.7 Hz, 3H, H-13). 13C NMR
(101 MHz, CDCl3) δ 158.8 (qC, C-1), 138.3 (qC, C-3),
133.0 (qC, C-6), 122.2 (CH, C-5), 121.4 (CH, C-4), 109.3
(CH, C-2), 97.2 (qC, C-11), 55.5 (qC, C-7), 43.7 (CH,
C-10), 42.6 (CH2, C-8), 34.6 (CH2, C-12), 31.5 (CH2, C-9),
22.9 (CH3, C-14), 21.5 (CH3, C-15), 13.8 (CH3, C-13).
Isolaurenisol: 2-[3-(Bromomethylene)-1,2-dimethylcyclo-
pentyl]-5-methylphenol (2)
Isolated as a white solid: 2.5 mg; [α] 20D = −7.2° (c 0.0025,
CH3OH); IRνmax 3,513 (O-H), 2,959 (C-H), 2,929, 2,870,
1,616 (C = C), 1,576 (C = C), 1,514, 1,454, 1,412, 1,294
(C-H), 1,254 (C-O), 1,186, 1,123, 809, 787, 653 (C-Br)
cm−1; 1H NMR (400 MHz, CDCl3) δ 7.15 (d, J = 7.9 Hz,
1H, H-5), 6.68 (dd, J = 7.9, 1.0 Hz, 1H, H-4), 6.57 (d,
J = 1.1 Hz, 1H, H-2), 5.99 (d, J = 2.0 Hz, 1H, H-13), 5.06
(s, 1H, OH), 3.05 to 2.95 (m, 1H, H-11), 2.56 (dt, J = 12.9,
7.2 Hz, 1H, H-8a), 2.25 (s, 3H, H-15), 2.07 to 1.96 (m, 1H,
H-9a), 1.64 to 1.57 (m, 1H, H-8b), 1.45 (s, 3H, H-14), 1.42
to 1.36 (m, 1H, H-9b), 1.22 (d, J = 7.2 Hz, 3H, H-12). 13C
NMR (101 MHz, CDCl3) δ 160.2 (qC, C-10), 153.3 (qC,
C-1), 138.0 (qC, C-3), 128.7 (qC, C-6), 128.1 (CH, C-5),
121.3 (CH, C-4), 118.2 (CH, C-2), 101.3 (CH, C-13), 52.0
(qC, C-7), 39.2 (CH, C-11), 39.2 (CH2, C-8), 31.0 (CH2, C-
9), 26.8 (CH3, H-14), 20.7 (CH3, C-15), 19.1 (CH3, C-12).
Debromoisolaurinterol: [(1R,3S)-1,3-dimethyl-2-methy-
lenecyclopentyl]-5-methyl-2-phenol (3)
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3,055 (C-H), 2,984 (C-H), 1,641 (C = C), 1,581 (C = C),
1,113 (C-H) cm−1; 1H NMR (400 MHz, CDCl3) δ 7.21 (d,
J = 8.0 Hz, 1H, H-5), 6.71 (dd, J = 8.0, 1.1 Hz, 1H, H-4),
6.65 (d, J = 1.4 Hz, 1H, H-2), 5.54 (s, 1H, OH), 5.08 (d,
J = 2.1 Hz, 1H, H-12a), 4.93 (d, J = 2.4 Hz, 1H, H-12b),
2.88 to 2.78 (m, 1H, H-10), 2.26 (s, 3H, H-15), 2.25 to
2.18 (m, 1H, H-8a), 2.07 to 1.98 (m, 1H, H-9a), 1.60 to
1.55 (m, 1H, H-8b, obscured), 1.46 (s, 3H, H-14), 1.41
to 1.36 (m, 1H, H-9b), 1.19 (d, J = 7.0 Hz, 3H, H-13).
Debromoaplysinol: 3a-methanol, 1,2,3,8b-Tetrahydro-
3,6,8b-trimethylcyclopenta-3H-[b]benzofuran (4)
Isolated as a colorless oil: ca 1 mg; [α] 20D = 0° (c 0.001,
CH3OH); IRνmax 3,425 (O-H), 2,940, 2,871, 1,588 (C = C),
1,499, 1,044 (C-O), 860 cm−1; 1H NMR (400 MHz, CDCl3)
δ 6.90 (d, J = 7.6 Hz, 1H, H-5), 6.66 (dd, J = 7.5, 0.7 Hz,
1H, H-4), 6.57 (s, 1H, H-2), 3.84 (dABq, J = 12.4(AB),
4.3 Hz, 1H, H-12a), 3.71 (dABq, J = 12.4(AB), 8.6 Hz, 1H,
H-12b), 2.28 (s, 3H, H-15), 1.88 to 1.78 (m, 2H, H-10,
H-8a), 1.72 (dd, J = 8.6, 4.3 Hz, 1H, OH), 1.66 to 1.60
(m, 2H, H-8b, H-9a), 1.46 (s, 3H, H-14), 1.16 to 1.11
(m, 1H, H-9b), 1.08 (d, J = 6.8 Hz, 3H, H-13). 13C NMR
(101 MHz, CDCl3) δ 159.1 (qC, C-1), 138.3 (qC, C-3),
133.3 (qC, C-6), 122.2 (CH, C-5), 121.2 (CH, C-4), 109.0
(CH, C-2), 99.6 (qC, C-11), 63.9 (CH2, C-12), 54.2 (qC,
C-7), 42.3 (CH, C-10), 42.3 (CH2, C-8), 31.5 (CH2, C-9),
22.9 (CH3, C-14), 21.2 (CH3, C-51), 13.7 (CH3, C-13).
Laur-11-en-10-ol. 3-(4′-Methylphenyl)-1,3,dimethyl-2-
methylidenecyclopentanol (5)
Isolated as a colorless oil: ca 1 mg; 1H NMR (600 MHz,
CDCl3) δ 7.21 (d, J = 7.9 Hz, 2H, H-1, H-5), 7.07 (d,
J = 8.1 Hz, 2H, H-2, H-4), 5.44 (s, 1H, H-12a), 4.99 (s, 1H,
H-12b), 3.47 (d, J = 5.9 Hz, 1H, OH), 2.29 (s, 3H, H-15),
2.08 to 2.04 (m, 1H, H-8a), 1.98 to 1.92 (m, 1H, H-8b),
1.82 to 1.77 (m, 1H, H-9a), 1.67 to 1.62 (m, 1H, H-9b,
obscured), 1.48 (s, 3H, H-14), 1.36 (s, 3H, H-13). 13C
NMR (151 MHz, CDCl3) δ 166.4 (qC, C-11), 145.4 (qC,
C-6), 135.3 (qC, C-3), 129.0 (2 × CH, C-2, C-4), 126.3
(2 × CH, C-1, C-5), 108.6 (CH2, C-12), 79.3 (qC, C-10),
50.3 (qC, C-7), 39.5 (CH2, C-8), 39.2 (CH2, C-9), 30.8




Isolated as a colorless oil: ca 1 mg; 1H NMR (600 MHz,
CDCl3) δ 6.92 (d, J = 7.6 Hz, 1H, H-5), 6.66 (d, J = 7.4 Hz,
1H, H-4), 6.49 (s, 1H, H-2), 5.35 (bs, 1H, OH), 2.26 (s, 3H,
H-15), 2.01 to 1.96 (m, 1H, H-8a, obscured), 1.76 to 1.71
(m, 1H, H-8b, obscured), 1.61 to 1.57 (m, 2H, H-9, ob-
scured), 1.39 (s, 3H, H-13), 1.38 (s, 3H, H-14), 1.28 (s, 3H,
H-12). 13C NMR (151 MHz, CDCl3) δ 158.0 (qC, C-1),
138.1 (qC, C-3), 133.5 (qC, C-6), 122.5 (CH, C-5), 121.0
(CH, C-4), 109.6 (CH, C-2), 100.5 (qC, C-11), 82.9 (qC,C-10), 53.6 (qC, C-7), 40.8 (CH2, C-8), 37.0 (CH2, C-9),




Isolated as a colorless oil: ca 0.1 mg; 1H NMR (600 MHz,
CDCl3) δ 5.84 (d, J = 10.4 Hz, 1H, H-4), 5.53 (d, J = 10.5 Hz,
1H, H-5), 5.22 (s, 1H, H-8), 4.63 (dd, J = 10.8, 6.3 Hz,
1H, H-10), 2.65 to 2.59 (m, 1H, H-9a), 2.57 to 2.50 (m,
1H, H-9b), 2.02 to 1.96 (m, 2H, H-1), 1.82 to 1.77 (m, 1H,
H-2a), 1.76 to 1.71 (m, 1H, H-2b, obscured), 1.55 (s, 3H,
H-14, obscured), 1.29 (s, 3H, H-15), 1.10 (s, 3H, H-13),
1.01 (s, 3H, H-12). 13C NMR (151 MHz, CDCl3) δ 139.0
(qC, C-7), 136.4 (CH, C-4), 131.1 (CH, C-5), 120.7 (CH,
C-8), 67.5 (qC, C-3), 61.3 (CH, C-10), 47.1 (qC, C-6), 41.5
(qC, C-11), 36.1 (CH2, C-2), 35.8 (CH2, C-9), 28.6 (CH3,
C-15), 28.2 (CH2, C-1), 26.1 (CH3, C-13), 21.7 (CH3,
C-14), 17.8 (CH3, C-12).
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Additional file 1: Structural characterization.
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